BeiGene still bleeding red ink despite blockbuster drug
The Chinese developer of next-generation cancer treatments is raking in huge returns from its flagship drug, but R&D and sales costs keep rising Key Takeaways: The Chinese biotech reported a…
Junshi hopes new scientist CEO can cure its woes
The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…
FAST NEWS: Junshi Biosciences announces A-Share buyback
The latest: Drug developer Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH) said on Sunday its board has approved a plan to buy back some of its A-shares for up to 58 yuan per…
Sales success comes with side effects for drug maker BeiGene
The Chinese biotech’s product revenues surged nearly 82% in the second quarter, driven by forecast-beating sales of its core cancer drugs Key Takeaways: Global sales of BeiGene's anti-tumor drug zanubrutinib…
Drug maker Junshi seeks Swiss cure for cash woes
The biotech aims to raise 3.4 billion yuan through Swiss GDRs in its second major fund-raising push in just over six months Key Takeaways: Junshi Biosciences reported dismal results in…
BeiGene goes for global growth with sales and R&D push
The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: BeiGene’s revenue in the…
Past the Peak? Covid Drugs Frenzy Cools as Pandemic Eases
Simcere Pharmaceutical and Junshi Biosciences have gained marketing approvals for their Covid oral drugs, but the market reaction has been lukewarmKey Takeaways:The drugs Xiannuoxin and Mindewei have been conditionally approved…